|Cleveland BioLabs and RUSNANO Enter Into Agreement. Antigenics Announces Clinical Data In Herpes Vaccine. Valeant Intends To Raise Offer For Afexa.|
|By Mary Davila|
|Monday, 26 September 2011 20:38|
Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced it has entered into an agreement with Open Joint Stock Company RUSNANO, a $10 billion Russian Federation fund with a mission to support high-tech and nanotechnology, to provide funding for CBLI's new subsidiary, Panacela Labs, Inc., which will develop a portfolio of new preclinical drug candidates.
According to the terms of the agreement, RUSNANO will invest up to $26 million over a four-year period, with an initial investment of $9 million financed upon closing of the agreement and three subsequent investments to be made upon achievement of development milestones and attraction of new investments to the project.
Cleveland BioLabs and RUSNANO will also be granted warrants providing options to increase their investment at two and four years following initial investment. The transaction is scheduled to close on or around September 30, 2011. Immediately after the closing, Cleveland BioLabs will have an initial ownership stake of approximately 55% in Panacela.
Antigenics, Inc. (OTC:ANTI) announced positive results from a randomized, four-arm Phase 1 study of HerpV, a recombinant (off-the-shelf) therapeutic vaccine for the treatment of genital herpes, which included the Company's QS-21 Stimulon adjuvant.
The results were published in the peer-reviewed journal Vaccine. HerpV is the most advanced HSV-2 vaccine currently in clinical development for the treatment of genital herpes. In this four-arm Phase 1 study, 35 herpes simplex virus type 2 seropositive patients received the vaccine plus QS-21 (HerpV), vaccine without QS-21, QS-21 alone, or placebo.
The vaccine was well tolerated, with injection site pain as the most commonly reported adverse event. Agenus plans to advance HerpV into a Phase 2 study in 2012 that will measure the effect of vaccination on viral shedding in individuals infected with HSV-2. Experts in HSV-2 clinical research believe that a reduction in viral shedding could translate into clinical benefit.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) announced it intends to raise its takeover offer for Afexa Life Sciences Inc. (OTC:AFXSF) of Edmonton, Alberta to $0.85 per common share, an increase of 20% from $0.71 originally offered under an agreement announced on August 30, 2011.
The increased offer is subject to Afexa's agreement to certain amendments to the support agreement, including a reduction in the minimum tender condition, which Valeant hopes to resolve in the coming days. Stikeman Elliott LLP is acting as legal counsel to Valeant and RBC Capital Markets is acting as financial advisor to Valeant.
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108.
Allied Healthcare International Inc. (NASDAQ: AHCI), a leading homecare provider of health and social care in the United Kingdom and Ireland, announced today that it had established a record date and a meeting date for the special meeting of shareholders to consider and vote upon the previously-announced merger agreement, dated as of July 28, 2011, pursuant to which Allied will be acquired by Saga Group Limited and related proposals.
ALR Technologies Inc. (OTCBB: ALRT) announces that on September 23, 2011, the Company submitted its reply to additional questions asked by the FDA in response to the Company's 510(k) application that was originally submitted to the FDA on July 23, 2010 for its proprietary Health-e-Connect (HeC) System.
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today urged its stockholders to take no action on the preliminary consent solicitation by Martin Shkreli, his firm, MSMB Capital Management LLC, and their respective affiliates, including Ironman Acquisition, LP and Ironman Acquisition GP, LLC (collectively, "MSMB").
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term results of the Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, has made a copy of the presentation shown at the Rodman and Renshaw 13th Annual Healthcare Conference available on the Company website at: www.AtheroNova.com .
BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced the appointment of Andrzej (Andy) Dzik-Jurasz, M.D., Ph.D. as Senior Medical Director for Medical Affairs, a newly created position.
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce shareholder guidance on the upcoming release of the first Cannabis Science brand of products. Cannabis extract-based products will initially be made available to licensed medical marijuana patients in Colorado.
Cellceutix Corporation (OTCQB: CTIX) (PINKSHEETS: CTIX) (the "Company"), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, today released pictures of its mice study with KM-133, the Company's small molecule acting on the principles of immune stimulation and PRINS reduction as a new treatment for psoriasis.
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it is tripling the number of patients in its Phase 1b/2 clinical trial who will be treated with its tumor-targeting doxorubicin conjugate INNO-206 at the dose planned for its Phase 2b trial for the treatment of advanced soft tissue sarcomas.
eHealthInsurance (NASDAQ: EHTH), the leading online source of health insurance for individuals and families, announced the release of a health insurance video to help college students better understand their coverage options.
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of ALIMTA® (pemetrexed for injection) as continuation maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer (mBC).
Luminex Corporation (NASDAQ: LMNX), today announced that it will host Planet xMAP Europe 2011, its annual European multiplexing technology symposium, September 28-29, 2011, at The Hofburg in Vienna, Austria.
MELA Sciences (NASDAQ: MELA) today announced that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter for the MelaFind® Pre-Market Approval (PMA) application.
MMRGlobal, Inc. (OTCBB: MMRF), a leading provider of Personal Health Records, MyEsafeDepositBox storage solutions and electronic document management systems for healthcare professionals, today announced that revenue from 30 MMRPro systems installed or in the process of being installed during the third quarter are projected to generate sales and deferred revenue of more than $600,000 plus patient revenue from MyMedicalRecords.com (www.mmrvideos.com) of an additional $5 million over the first 12 months following completion of the current quarter's installations.
NanoViricides, Inc. (OTC BB: NNVC) announced that its President, Dr. Anil R. Diwan, will present at the 10th Annual NanoBusiness Conference/NanoManufacturing Summit being held at the Seaport World Trade Center in Boston, MA, today.
NHS Health Solutions, Inc. (PINKSHEETS: NHSH), as previously announced, has formally entered into a binding Letter of Intent with Mineseeker Operations Overseas Limited (hereinafter, "Mineseeker") in order to fully acquire Mineseeker as a wholly owned subsidiary.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the appointment of Eric Pauwels as senior vice president and chief commercial officer.
PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced the appointment of Brian A. Markison to the Company's Board of Directors, effective September 22, 2011.
Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, today issued an update to its shareholders recapping recent activities and highlights.
Radient Pharmaceuticals Corporation (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has signed a Regional Distributor Partner Agreement with Irvine-based TS Pharm, Inc.
Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) announced today that on-going discussions with a major biotechnology company have advanced to the negotiation of a Material Transfer Agreement (MTA) which was received in draft this week by Stellar, for use of the Company's KLH in joint research into the functional characterization of various preparations of KLH.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced that results of a Phase 1 study of ganetespib in combination with docetaxel in solid tumors were presented at the Annual Meeting of the European Society of Medical Oncology in Stockholm, Sweden. Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90) currently being studied in a broad range of clinical trials with over 400 patients treated to date.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will acquire the 50% interest formerly held by Kowa Company Ltd. in Teva's Japanese joint venture for a total purchase price of $150 million.
Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched Norethindrone and Ethinyl Estradiol Tablets (Chewable), 0.4 mg/0.035 mg and Ferrous Fumarate Tablets (Chewable), 75 mg, a generic version of Warner Chilcott's FEMCON(R) Fe. Watson began shipping the product today.
YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM),a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.